close

Endo Pharmaceuticals Holdings Inc., a pharmaceutical company, engages in the research, development, sale, and marketing of branded and generic prescription pharmaceuticals for treating and managing pain primarily in the United States. Its products include Lidoderm, a topical patch product for the relief of the pain associated with post-herpetic neuralgia; Opana ER and Opana for the relief of moderate-to-severe pain in patients; Percocet and Percodan tablets; Frova for the treatment of migraine headaches in adults; and Voltaren Gel for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company's products also include Sanctura for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency; Sanctura XR to treat OAB symptoms; Supprelin LA for treating central precocious puberty (CPP) or the early onset of puberty in children; Vantas provides histrelin, a luteinizing hormone-releasing hormone (LHRH) agonist, for the palliative treatment of advanced prostate cancer; Delatestryl for the treatment of male hypogonadism; Hydron Implant; and Valstar, a sterile solution of valrubicin for intravesical instillation. Its development stage products include Nebido for treatment of hypogonadisml; PRO 2000, a Phase III clinical stage product for the prevention of infection by HIV and other sexually-transmitted pathogens; octreotide implant, a Phase III clinical stage product for the treatment of acromegaly; and axomadol, a Phase II clinical stage product for the treatment of moderate to moderately severe chronic pain and diabetic peripheral neuropathic pain. The company's generic products include Morphine Sulfate and Endocet, an oxycodone hydrochloride and acetaminophen product. It has strategic alliances with Novartis AG, Hind Healthcare, Penwest Pharmaceuticals Co., and Vernalis Development Limited. The company was founded in 1997 and is headquartered in Chadds Ford, Pennsylvania.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	35.88
Volume	(mio) 1.33
Volume Avg	(mio) 1.54
52 Week High	44.53
52 Week Low	26.02
PE	23.17
PE (group average)	39
EPS Year	1.55
EPS change Q/Q	-40%
EPS change Q/Q Yr ago	-5.88%
EPS change Q/Q next Q est	-61.6%
EPS change Y/Y	11.87%
REV change Q/Q	9.55%
REV change Q/Q Yr ago	53.68%
EPS next Q est	1.25
EPS next Y est	5.81
Divident Annual	0.00
Dividend Yield	0%